ACGN - Aceragen - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

63.57M

Cash

12.04M

Avg Qtr Burn

-6.124M

Short % of Float

5.66%

Insider Ownership

68.95%

Institutional Own.

2.26%

Qtr Updated

12/31/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ACG-701 Details Cystic fibrosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACG-701 Details Melioidosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACG-801 Details Farber Disease	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tilsotolimod (tilsotolimod + ipilimumab/ nivolumab) Details Colorectal cancer , Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tilsotolimod (IMO-2125 + ipilimumab) Details Melanoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.